Wird geladen...
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
Recently, the standard of care for metastatic Castration Resistant Prostate Cancer (mCRPC) has changed considerably. Persistent androgen receptor (AR) signaling has been identified as a target for novel therapies and reengages the fact that AR continues to be the primary target responsible for metas...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4167156/ https://ncbi.nlm.nih.gov/pubmed/25062956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2490-14-55 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|